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Cardiomyopathies represent an important cause of cardiovascular morbidity and mortality due to heart failure, arrhythmias, and sudden
death. Most forms of hypertrophic cardiomyopathy (HCM) are familial with an autosomal-dominant mode of inheritance. Over the last
20 years, the genetic basis of the disease has been largely unravelled. HCM is considered as a sarcomeropathy involving mutations in sarco-
meric proteins, most often b-myosin heavy chain and cardiac myosin-binding protein C. ‘Missense’ mutations, more common in the former,
are associated with dysfunctional proteins stably integrated into the sarcomere. ‘Nonsense’ and frameshift mutations, more common in the
latter, are associated with low mRNA and protein levels derived from the diseased allele, leading to haploinsufficiency of the remaining
healthy allele. The two quality control systems responsible for the removal of the affected mRNAs and proteins are the nonsense-mediated
mRNA decay (NMD) and the ubiquitin-proteasome system (UPS), respectively. This review discusses clinical and genetic aspects of HCM
and the role of NMD and UPS in the regulation of mutant proteins, evidence for impairment of UPS as a pathogenic factor, as well as
potential therapies for HCM.
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1. Hypertrophic cardiomyopathy:
a disease of the sarcomere
1.1. Clinical aspects
Cardiomyopathies are defined as diseases of the myocardium with
cardiac dysfunction and are classified into four main categories:
hypertrophic (HCM), dilated (DCM), arrhythmogenic right ventri-
cular, and restrictive.1,2 HCM is characterized by left ventricular
hypertrophy (LVH), which predominantly involves the interventri-
cular septum, LV outflow tract obstruction, and diastolic dysfunc-
tion. HCM is associated with marked myocardial and myofibrillar
disarray as well as increased interstitial fibrosis. The disease preva-
lence has been estimated at approximately 1:500 in young adults.3
HCM is therefore much more common than previously recog-
nized; in fact, it is one of the most common monogenic diseases.
The diagnosis of HCM is usually made incidentally or after the
diagnosis of a family member with sudden death. Diagnosis relies
on physical examination, two-dimensional echocardiography, elec-
trocardiography (ECG), and family history.4 Echocardiographic cri-
teria include an LV wall thickness 15 mm, in the absence of
another cardiac or systemic disease that could induce this hyper-
trophy (e.g. hypertension or aortic stenosis). ECGs have diagnostic
value in raising a suspicion of HCM in family members without LVH
on echocardiography. Genetic testing in the laboratory can also be
performed to rule out ‘phenocopy’ diseases and to identify the
specific mutations.5,6 Although endomyocardial biopsy is not
required for patients with suspected HCM, it would be relevant
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in differentiating HCM with other known causes of increased LV
wall thickness, e.g. infiltrative disorders such as amyloidosis, and
storage disorders such as Fabry disease.7 In addition, myectomy
is considered to be the most appropriate surgical treatment for
patients with obstructive HCM. Finally, biopsy is relevant for inves-
tigating the molecular mechanisms of HCM.
The clinical course of HCM is highly variable and is associated
with an increased risk of sudden death. Whereas most patients
are asymptomatic, HCM patients may present with symptoms of
congestive heart failure with exertional dyspnoea and chest pain
but usually preserved systolic function, and atrial fibrillation.
Sudden death has been recognized as the most devastating conse-
quence of HCM in young adults and particularly young athletes
since the first modern description of the disease.8 The presence
of at least one of the following clinical indicators has been
shown to be associated with increased risk of sudden death and
therefore should require implantable cardioverter–defibrillator
placement (for detailed reviews, see 9,10): history of sudden
death in first-degree family members, prior cardiac arrest, sus-
tained ventricular tachycardia, bursts of non-sustained ventricular
tachycardia on serial Holter ECGs, abnormal blood pressure
during exercise, and massive (.30 mm) LVH.9,11 The incidence
of sudden death has been evaluated to be 1%/year in adult
HCM patients12 and as high as 3–5% in HCM patients with mul-
tiple risk factors.9 Dyspnoea is the most common symptom in
HCM (90% of patients), which is mainly the consequence of dias-
tolic dysfunction. However, it could also be the consequence of
systolic dysfunction in the minority of HCM patients (5–10%)
who evolved into a ‘burned-out’ phase characterized by LV dilation
and wall thinning often resembling the features of DCM and pro-
ducing progressive and irreversible heart failure.13 Atrial fibrillation
is the most common sustained arrhythmia in HCM justifying
aggressive treatments, and paroxysmal episodes of chronic atrial
fibrillation occur in 20–25% of HCM patients and are strongly
associated with left atrial enlargement and increasing age.9
1.2. Mutations in myosin heavy chain
and myosin-binding protein are most
common
HCM is familial in the majority of cases and is inherited in an
autosomal-dominant pattern with an incomplete penetrance.6,14,15
HCM involves more than 450 different mutations in at least 13
genes encoding proteins of the sarcomere (Table 1; for reviews,
see 16–18). Therefore HCM is recognized as a sarcomeropathy.
Most HCM patients are heterozygous for the mutation, but in
3–5% of cases, patients carry two mutations (in the same or differ-
ent genes). This is generally associated with a severe phenotype
and bad prognosis suggesting a gene-dosage effect.19 The two
most frequently mutated genes (82% of the genotyped patients)
are MYH7 and MYBPC3, encoding b-myosin heavy chain (b-MHC)
and cardiac myosin-binding protein C (cMyBP-C), respectively.19
Both proteins are major components of the sarcomere thick fila-
ment. Myosin is the molecular motor that transduces energy
from the hydrolysis of ATP into directed movement and drives sar-
comere shortening and muscle contraction. cMyBP-C is expressed
only in the heart of mammals and has both structural and
regulatory roles in cardiac muscle20,21 (reviewed in 22). Recent
data using cMyBP-C-deficient mice demonstrated that cMyBP-C
reduces Ca2þ sensitivity of the myofilament at low Ca2þ concen-
trations and sarcomere length23 and thereby likely allows complete
relaxation in diastole.24,25
HCM exhibits wide phenotypic heterogeneity among affected
subjects, characterized by a variable degree of hypertrophy and
prognosis. Part of this is explained by locus heterogeneity. For
instance, MYBPC3 mutations are usually associated with a delayed
onset, a lower penetrance, a milder degree of hypertrophy, and
better survival compared with MYH7.26 –28 Moreover, genetic
studies have revealed that 25% of individuals carrying the
mutation of first-degree relatives with typical HCM are clinically
unaffected.29,30 This suggests the existence of modifier genes,
which modulate the phenotypic expression of the disease. Associ-
ations have been found with polymorphisms in genes for the angio-
tensin I-converting enzyme and AT1 and AT2 receptors.31,32
Recently, a polymorphism in the calmodulin III promoter has
been shown to contribute to the phenotype in HCM patients car-
rying a mutation in either MYH7 or MYBPC3.33
2. Quality control systems for
mutant mRNAs and proteins
About 200 different mutations were identified in MYH7 and are
almost exclusively missense (Table 1). Some of them have been
analysed experimentally and were shown to result in stable
mutant proteins in human samples34– 36 and normal incorporation
into the sarcomere after gene transfer in cardiac myocytes.37
These data suggest that missense proteins are present at normal
levels in the sarcomere and act as ‘poison polypeptides’ through
a dominant-negative effect.
In contrast, 70% of MYBPC3 mutations are nonsense or frame-
shift.17,30 Nonsense mutations, by definition, introduce a prema-
ture termination codon (PTC) at the place of mutations (e.g. by
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Sarcomeric genes and mutations involved in
familial HCM





b-MHC MYH7 212 47
cMyBP-C MYBPC3 165 37
Cardiac troponin T TNNT2 33 7
a-Tropomyosin TPM1 12 3
Regulatory myosin light chain MYL2 10 2
Cardiac actin ACTC1 7 1.5
Essential myosin light chain MYL3 5 1.1
Muscle LIM protein CSRP3 3 ,1
Titin TTN 2 ,1
Telethonin (T-cap) TCAP 2 ,1
Cardiac troponin C TNNC1 1 ,1
a-MHC MYH6 1 ,1
Adapted from Richard et al.17 and Alcalai et al.18
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changing CGA to TGA), whereas frameshift mutations result from
an insertion or deletion and create a PTC downstream. Both are
expected to produce C-terminal truncated cMyBP-Cs. The mech-
anisms by which MYBPC3 mutations lead to HCM remain elusive
and are in the focus of this review. Truncated cMyBP-Cs have
been consistently undetectable by western blot in myocardial
tissue from patients carrying a frameshift mutation,38 –40 after
gene transfer in cardiac myocytes37 or in transgenic mice.41
Thus, the prevailing data suggest that mutant mRNAs and/or pro-
teins are unstable and quantitatively degraded. Nonsense and fra-
meshift mutations would therefore act as ‘null alleles’, causing
cMyBP-C haploinsufficiency in heterozygous patients. An insuffi-
cient amount of normal full-length cMyBP-C could produce an
imbalance in the stoichiometry of the thick filament components
and alter sarcomeric structure and function. Indeed, heterozygous
cMyBP-C-deficient mice carrying only one functional allele exhibit
marked activation of the JNK and p38 MAPK pathway and induc-
tion of apoptosis,42 followed by asymmetric septal hypertrophy.43
Two major quality control systems, nonsense-mediated mRNA
decay (NMD) and ubiquitin-proteasome system (UPS), contribute
to low levels of mutant proteins.
2.1. Nonsense-mediated mRNA decay
The NMD is an evolutionary conserved surveillance pathway in all
eukaryotes examined to date. NMD targets PTC-containing tran-
scripts for rapid degradation, thereby protecting the organism
from the deleterious dominant-negative or gain-of-function
effects of resulting C-terminal truncated proteins (Figure 1) (for
details, see 44–46). The general rule is that NMD occurs when
a PTC is located more than 50–55 nucleotides upstream of the
last exon–exon junction within the mRNA, and NMD requires
at least one intron and components of translation.47
The role of NMD in genetic disease has been well described for
Duchenne muscular dystrophy (DMD) and cystic fibrosis (for
review, see 48), but has just begun to be recognized in cardiac
genetic diseases. Lamin A/C mutations associated with DCM
result in much lower level of PTC-bearing transcripts,49,50 which
were stabilized by the translation inhibitor cycloheximide, support-
ing involvement of NMD.50 Similar data were obtained for non-
sense mutations in ether-a-go-go-related gene in human long-QT
syndrome.51 As described above, frameshift MYBPC3 mutations
in human HCM were also associated with lower amount of
nonsense than wild-type mRNA, suggesting involvement of
Figure 1 The NMD. (A) A PTC located more than 50–55 nucleotides (nt) upstream of the last exon–exon junction within the mRNA (green
region) elicits NMD, whereas mRNAs with PTCs downstream of this boundary (red region) escape NMD. (B) Mechanism of the action of
NMD. During pre-mRNA splicing, a protein complex called exon junction complex (EJC) is deposited 20–24 nucleotides upstream of
every exon–exon junction and functions hereby as a marker to dictate whether a stop codon is premature or not. The EJC containing the
up-frameshift (UPF) 3 protein remains bound to the mRNA when exported to the cytoplasm. Here, a second NMD core protein, UPF2,
binds to UPF3. In normal mRNAs, the EJCs are then displaced by the ribosome during the pioneer round of translation, and translation
stops when the ribosome reaches the normal stop codon (B, top). In contrast, in PTC-bearing mRNAs, the ribosome is blocked at the
PTC, and the EJC downstream of the PTC remains associated with the mRNA, because it cannot be displaced by the ribosome (B,
bottom). This results in attachment of the so-called SURF complex, which comprises SMG-1 (suppressor with morphogenetic effect on geni-
talia), UPF1, and the eukaryotic release factors (eRF) 1 and eRF3, to the ribosome. Binding of UPF2 to UPF1 leads to its phosphorylation by
SMG-1, which in turn drives dissociation of eRF1 and eRF3 and binding of SMG-7. Ultimately, the mRNA is degraded by different pathways
including decapping or deadenylation. Figure adapted from Garneau et al.46
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NMD.39,40 We recently demonstrated that NMD specifically regu-
lates the level of PTC-bearing, but not of other cMyBP-C tran-
scripts in a mouse model of HCM.52
2.2. The UPS
Like NMD for nonsense mRNAs, quality control for aberrant pro-
teins exists. Most cytosolic, nuclear, and myofibrillar proteins are
degraded via the UPS, whereas membrane proteins and organelles
are degraded by lysosomes via autophagy (for review, see 53). A
major function of the UPS is to prevent accumulation of
damaged, misfolded, and mutant proteins, but the system is also
involved in intracellular signalling, transcriptional control, or regu-
lation of cell death.53 The UPS functions as an ATP-dependent pro-
teolytic system that requires polyubiquitination via lysine 48
residues of the target protein prior to its degradation by the 26S
proteasome (Figure 2).54 Polyubiquitination involves the concerted
action of 3 enzymes: E1 (ubiquitin-activating), E2 (ubiquitin-
conjugating), and E3 (ubiquitin ligase), the latter affording substrate
specificity. The eukaryotic 26S proteasome is a large, multicatalytic
protein complex composed of the 19S regulatory complex and the
20S proteasome (for reviews, see 54,55). The damaged, misfolded,
or mutant proteins are degraded by three major peptidase activi-
ties (chymotrypsin-like, trypsin-like, and caspase-like) residing on
the inner surface of the b-rings of the 20S proteasome (for a
detailed review in the same issue, see 56).
The role of the UPS in regulating levels of mutant proteins in
HCM has been first suspected by the analysis of myocardial
tissue of HCM patients with MYBPC3 frameshift mutations, in
which the C-terminal truncated cMyBP-C proteins were never
detected despite the presence of (low levels) of nonsense
mRNAs.38–40 This suggests that, in addition to NMD, the trans-
lation rate of the pathological mRNAs is low or protein degra-
dation rate is high. Support for the latter hypothesis comes from
studies overexpressing human truncated cMyBP-Cs in cardiomyo-
cytes or transgenic mice. Despite normal levels of nonsense
mRNA, protein levels of truncated cMyBP-C were very
low,37,41,57 and blockade of the UPS markedly increased protein
levels.57 Recent data suggest that the muscle-specific E3 ubiquitin
ligase atrogin-1 is involved in this process.58 The signals that
cause quantitative degradation of truncated proteins by the UPS
are not clear. Absence of biomolecular interaction between trun-
cated cMyBP-C and human b-MHC59 could promote degradation
of truncated cMyBP-C. More likely, truncation and/or the incor-
poration of new ‘nonsense’ amino acids after the frameshift
causes misfolding, and this constitutes a signal for UPS targeting.
In line with this idea, a missense cMyBP-C was recently shown
to be degraded by the UPS, potentially due to the presence of a
new lysine residue in the mutant, which could allow its polyubiqui-
tination.60 Importantly, our recent data obtained with a mouse
model of HCM provide evidence that the UPS also regulates the
level of aberrant mutant cMyBP-C in vivo.52
Taken together, the data obtained with cMyBP-C mutations
associated with HCM suggest that NMD and UPS act as two con-
secutive quality control systems to effectively eliminate mutant
proteins. The mutated allele is thus a functional null allele and
the disease is likely caused by a relative lack of wild-type
cMyBP-C in the sarcomere, i.e. by the mechanism of haploinsuffi-
ciency. In the following sections, we will discuss whether involve-
ment of the UPS per se may constitute a pathogenic mechanism
in HCM and whether interfering with NMD or UPS could rep-
resent a valuable therapeutic strategy.
3. Alterations of the UPS
in cardiac disease
3.1. Impaired UPS in familial HCM
and DCM
Apart from the involvement of UPS in degrading mutant proteins in
HCM, recent investigations suggest that UPS impairment might
play a role in the pathophysiology of HCM and desmin-related car-
diomyopathy (DRM). DRM is an autosomal-dominant disorder
Figure 2 The UPS. The UPS functions as an ATP-dependent proteolytic system that requires polyubiquitination via lysine 48 residues of the
target protein prior to its degradation by the 26S proteasome. Polyubiquitination involves the concerted action of three enzymes: E1
(ubiquitin-activating), E2 (ubiquitin-conjugating), and E3 (ubiquitin ligase), the latter affording substrate specificity. The eukaryotic 26S protea-
some is a large, multicatalytic protein complex composed of the 19S regulatory complex and the 20S proteasome. The damaged, misfolded, or
mutant proteins are degraded by three major peptidase activities (chymotrypsin-like, trypsin-like, and caspase-like).
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characterized by marked accumulation of desmin in skeletal and
cardiac muscle.61 aB-crystallin (CryAB) is the most abundant
heat shock protein in the heart and stabilizes desmin. A missense
R120G CryAB mutation leads to DRM.62 Transgenic mice
expressing a CryABR120G mutant develop HCM, which gradually
progresses to heart failure.63 Perinuclear aggregates of desmin
and preamyloid oligomer in cardiomyocytes64 suggest that
CryAB-DRM is a subclass of the aggresomal and amyloid-related
neurodegenerative disorders such as Alzheimer’s and Parkinson’s
diseases.64 Using GFPdgn reporter mice, in which modified GFP
is used as a UPS substrate, aggregates and marked UPS impairment
were detected in CryABR120G mice.65 Similar UPS impairment was
found in another DRM mouse model associated with a desmin
mutation.66,67 The molecular mechanism by which aggregates
impair the UPS is not clear. It has been proposed that aggregated
proteins directly inhibit the 26S proteasome by ‘chocking’ the pro-
teases. Alternatively, protein aggregates may indirectly interfere
with UPS function by inactivating or depleting UPS components.
Adenoviral expression of truncated cMyBP-C in cardiomyocytes
resulted in the formation of ubiquitin-positive aggregates of trun-
cated cMyBP-C and impairment of the UPS as evidenced with a
GFP-reporter system.57 Overexpression of missense cMyBP-C in
COS cells also reduced proteasome activity and increased apopto-
sis.60 Adrenergic stress-induced hypertrophy revealed a decrease
in proteasome activity in heterozygous cMyBP-C mutant mice car-
rying both mutant and wild-type alleles, but not in heterozygous
cMyBP-C null mice carrying only a functional allele.68 The mechan-
ism by which the UPS was impaired under the different conditions
has not been elucidated. However, one could speculate that
cMyBP-C mutants, similar to misfolded desmin, chock the protea-
some and/or compete with other degradation-prone proteins for
UPS removal. This could result in the accumulation of factors regu-
lated by the UPS such as transcription factors involved in the
hypertrophic response (e.g. SRF, GATA4) or apoptosis (e.g. p53).
Viewed from this angle, UPS impairment could contribute to the
pathogenesis of HCM.
3.2. Altered UPS in cardiac hypertrophy
and heart failure
Is UPS impairment a common feature of LV hypertrophy? A series
of investigations indeed reported UPS abnormalities in various
cardiac diseases (for review, see 54). Accumulation of ubiquiti-
nated proteins appears to be almost a stereotypic finding in
cardiac hypertrophy. But it becomes increasingly clear that
increased steady-state levels of ubiquitinated proteins do not
necessarily indicate impairment of the UPS. Instead, they are
often associated with increase in proteasomal activity (measured
with fluorogenic substrates) and/or ubiquitinating or deubiquitinat-
ing enzymes. Thus, it is important to keep in mind that steady-state
levels of ubiquitinated proteins reflect the balance of several vari-
ables: the production rate of misfolded proteins, their ubiquitina-
tion, deubiquitination, and finally degradation.
In a mouse model of pressure overload-induced LV hypertro-
phy, increased levels of ubiquitinated proteins were associated
with depressed proteasome activities and induction of apoptosis.
These alterations preceded the onset of cardiac dysfunction,69
suggesting that UPS dysfunction could be a causative factor. On
the other hand, in a rat model of pressure overload-induced
cardiac hypertrophy, ubiquitin B, the E2-conjugating enzyme
UbcH2, the E3 ubiquitin ligases atrogin-1 and MuRF1, and the pro-
teasomal subunit PSMB4 transcripts were all increased after 7
days.70 In a feline model of pressure overload-induced cardiac
hypertrophy, transient accumulation of ubiquitinated proteins
was identified as well as increased levels of numerous E3 ubiquitin
ligases.71 Increased steady-state levels of ubiquitinated proteins
associated with greater proteasome activities were also found in
genetically engineered mouse models with HCM or DCM.65,72
Interestingly, increased chymotrypsin-like activities followed the
development of LV hypertrophy in homozygous cMyBP-C-
targeted mutant mice72 and the development of heart failure in
transgenic CryABR120G mutant mice.65 In terminally failing human
hearts, marked accumulation of ubiquitinated proteins was associ-
ated with the upregulation of several UPS components.73 More-
over, a well-known UPS target, the proapoptotic p53, was
recently found to be increased in human DCM.74 This was associ-
ated with increased levels of the p53-specific E3 ubiquitin ligase
MDM2 and increased chymotrypsin-like activity, but also increased
levels of the deubiquitinating enzyme HAUSP.74 The interpretation
of this counterintuitive finding was that the increase in HAUSP
overrides the increase in MDM2, pointing to the complexity of
the system.
Taken together, these data show that measurements of single
components of the UPS are not sufficient to conclude about the
state of the system and that the role of the UPS in cardiac
disease is just beginning to be unravelled. A few statements can
be made with some certainty: (i) the steady-state level of ubiquiti-
nated proteins integrates numerous factors and is not directly
indicative of the degradation capacity of the proteasome in vivo;
(ii) an increase in an E3 ubiquitin ligase does not allow the con-
clusion that its substrates are decreased; (iii) impairment of the
UPS in vivo, i.e. a mismatch between the level of UPS-targeted pro-
teins and proteasomal capacity, can be determined by
UPS-reporter systems; (iv) accumulation of ubiquitinated proteins
occurs regularly during hypertrophy and other states of remodel-
ling; and (v) increased proteasome activities during hypertrophy
and ‘cardiac stress’ are likely mechanisms to cope with increased
appearance of misfolded proteins (e.g. by energy deficit, oxidative
stress, overload of sarcomeres). When the latter exceeds the
degradation capacity of the UPS, misfolded proteins may accumu-
late and form aggregates as described in DRM. In addition, any
imbalance of ubiquitinating and deubiquitinating enzymes and pro-
teasomal activity could contribute to cardiac pathology by dysregu-
lation of specific factors such as p53, SRF, GATA4, or the inducible
cAMP early repressor (ICER), as suggested previously.75 Much
more work is needed to fully understand the relative contribution
of these processes and the key factors.
4. Targeting nonsense mRNA or
the UPS for HCM therapy?
Different approaches have been used and are summarized in
Table 2.
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4.1. Targeting nonsense mRNA?
Nearly 30% of mutations identified in human genetic diseases
result in PTC-bearing transcripts that are degraded by NMD.
The biological sense of this system probably lies in the elimination
at the transcript level of non-functional proteins that can have a
dominant-negative effect; the downside is haploinsufficiency. Selec-
tive inhibition of NMD may provide a strategy to rescue the phe-
notype in those cases, in which the mutant protein shows no
dominant-negative effect and has a near-normal function. The
experimental NMD inhibitor wortmannin inhibits the
PI3-kinase-related protein SMG-1 that phosphorylates UPF1
during NMD.76 Owing to its cytotoxic effects, wortmannin is unac-
ceptable as a therapeutic agent in humans, but siRNA-mediated
knockdown of SMG-1 or UPF1 restored the level of PTC-bearing
collagen VI-2 mRNA and rescued the phenotype in fibroblasts of a
patient with Ullrich’s disease.77
An alternative are drugs that target the detection of PTCs. They
have been tested in animal models and patients with cystic fibrosis
and DMD (for review, see 48). By enforcing reading through PTCs,
these therapies can induce the synthesis of full-length proteins in
case of nonsense mutations. However, PTC readthrough is unlikely
of value in case of frameshift mutations resulting in PTC, because
all the amino acids after the frameshift are expected to be non-
functional. Different PTC readthrough mechanisms are known.
For example, aminoglycosides affect the decoding site of ribo-
somes and promote the incorporation of an amino acid at a
PTC.48 The aminoglycoside gentamicin has been already used in
human patients to suppress PTC-bearing transcripts associated
with cystic fibrosis78 and DMD.79 However, responses to gentami-
cin varied widely from one study to the other. Several factors may
account for this variability including the identity and surrounding
sequences of the PTC, the amount of PTC-bearing transcripts,
and the duration of treatment (see 48 for details). The usefulness
of aminoglycosides is also limited because of severe side effects,
including kidney damage, hearing loss, and tinnitus.80,81 Recently,
a new non-aminoglycoside, orally bioavailable compound,
PTC124, has been developed for the sole purpose of inducing
selective ribosomal PTC readthrough.82 In contrast to aminoclyco-
sides, PTC24 has not evoked kidney failure or deafness in phase I of
safety trials.82
Alternative RNA-based therapies, developed over the last
decade, present a unique potential for native mRNA modification
within the endogenous regulatory environment (for review, see
83). The active targeting molecules are usually short antisense oli-
goribonucleotides that can block cryptic splicing, or exclude/
include one or more exons to restore the reading frame. These
RNA-targeting therapeutics could be well suited to treat HCM.
4.2. Targeting the UPS?
As discussed above, impairment of UPS function appears to be
common in cardiac disease and may be even causally related to
the progression to heart failure. Global inhibition of the UPS
is therefore expected to worsen rather than to rescue the
phenotype. However, partial inhibition of the UPS could
theoretically lead to preferential accumulation of factors such as
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hypertrophy-repressor ICER that could have beneficial conse-
quences and may underlie positive results seen in animal models.
For example, low concentrations of MG132 prevented hypertro-
phy in neonatal rat cardiomyocytes, and low doses of the
FDA-approved proteasome inhibitor Velcadew effectively
reduced spontaneous cardiac hypertrophy in hypertensive rats.84
Two additional studies have demonstrated that proteasome inhi-
bition can induce regression of established cardiac hypertrophy.
In the first model of isoprenaline-induced cardiac hypertrophy,
the proteasome inhibitor PS-519 induced significant regression of
hypertrophy.85 In a mouse model of pressure overload, the protea-
some inhibitor epoxomicin inhibited cardiac hypertrophy, reduced
apoptosis, and stabilized ejection fraction.86 Of note however, car-
diomyopathic side effects have been reported in patients using pro-
teasome inhibitors for longer periods of time,87–89 raising
concerns about their utility for therapy.
Therapies designed to regulate specific E3 ubiquitin ligases have
not been developed for the heart but in cancer. The E3 ubiquitin
ligase MDM2 is commonly overexpressed in cancer and regulates
p53 levels, and small-molecule inhibitors of MDM2 have been
recently shown to induce cancer cell death by stabilizing p53.90
Targeting the E3 ubiquitin ligases MDM2, atrogin-1, or MuRF1 in
cardiac hypertrophy is likely not a suitable strategy, because the
latter has been shown to be cardioprotective, and inhibiting
MDM2 would enhance cardiac apoptosis (see recent reviews
54,91). But targeting the E3 ubiquitin ligases for HIF1a, IkB, or
ICER could have beneficial consequences.
In cases of HCM, where the remaining PTC-bearing transcripts
are detected,38–40 partial inhibition of the proteasome or selective
targeting of the responsible E3 ligase could be a treatment of
choice if the truncated protein is functional. Such approach has
not yet been tested in cardiac disease, but inhibition of the protea-
some in vivo restored the expression of truncated dystrophin at the
sarcolemma and reduced muscle membrane damage in skeletal
muscles of mdx mice.92
5. Conclusion
NMD and UPS are two quality control systems directed towards
eliminating potentially harmful abnormal proteins. In HCM associ-
ated with MYBPC3 mutations, elimination of aberrant mRNA and
proteins resulting from nonsense or frameshift mutations causes
a functional null allele and haploinsufficiency. In cases where the
aberrant protein is expected to be functional and non-toxic, inter-
ference with NMD or underlying RNA-editing mechanisms could
(partially) correct the defect. Whether deficient production of
cMyBP-C is sufficient to explain the phenotype of HCM or
whether incomplete elimination of mutant proteins and/or impair-
ment of the UPS play an additional pathogenic role is still not
entirely clear. Both increases and decreases in UPS function are
regularly observed in animal models of HCM, cardiac hypertrophy,
and heart failure, suggesting that regulation of the UPS belongs to
the important adaptations in cardiac disease. Pharmacological pro-
teasome inhibitors were associated with antihypertrophic effects
and improved function in animals models, which is probably not
the consequence of a global decrease in UPS capacity, but rather
a preferential interference with the degradation of
antihypertrophic or otherwise beneficial factors particularly sensi-
tive to UPS inhibition. Better understanding of these processes
may allow the development of specific inhibitors devoid of the
risks of general UPS inhibition and establish the UPS as a promising
target in the therapy of cardiac diseases.
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and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc
Res 2010;85:357–366.
59. Flavigny J, Robert P, Camelin J, Schwartz K, Carrier L, Berebbi-Bertrand I. Biomo-
lecular interactions between human recombinant b-MyHC and cMyBP-Cs impli-
cated in familial hypertrophic cardiomyopathy. Cardiovasc Res 2003;60:388–396.
60. Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E et al.
Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-
binding protein C mutation and associated with cardiac dysfunction in hyper-
trophic cardiomyopathy. J Mol Biol 2008;384:896–907.
61. Rappaport L, Contard F, Samuel JL, Delcayre C, Marotte F, Tome F et al. Storage
of phosphorylated desmin in a familial myopathy. FEBS Lett 1988;231:421–425.
62. Vicart P, Caron A, Guicheney P, Li Z, Prevost MC, Faure A et al. A missense
mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopa-
thy. Nat Genet 1998;20:92–95.
63. Wang X, Osinska H, Klevitsky R, Gerdes AM, Nieman M, Lorenz J et al.
Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-
crystallin aggregation and cardiomyopathy in mice. Circ Res 2001;89:84–91.
64. Sanbe A, Osinska H, Villa C, Gulick J, Klevitsky R, Glabe CG et al. Reversal of
amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl
Acad Sci USA 2005;102:13592–13597.
65. Chen Q, Liu JB, Horak KM, Zheng H, Kumarapeli AR, Li J et al. Intrasarcoplasmic
amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by
compromising substrate uptake. Circ Res 2005;97:1018–1026.
66. Liu J, Chen Q, Huang W, Horak KM, Zheng H, Mestril R et al. Impairment of the
ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J 2006;20:
362–364.
UPS and NMD in HCM 337
67. Liu J, Tang M, Mestril R, Wang X. Aberrant protein aggregation is essential for a
mutant desmin to impair the proteolytic function of the ubiquitin-proteasome
system in cardiomyocytes. J Mol Cell Cardiol 2006;40:451–454.
68. Schuermann F, Schlossarek S, Mearini G, Geertz B, Vignier N, Eschenhagen T et al.
Adrenergic stress unmasks exaggerated septal hypertrophy and proteasome
impairment in heterozygous cMyBP-C mutant mice. (Abstract). Circulation 2008;
118:S521–S521.
69. Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, Kato H et al.
Depression of proteasome activities during the progression of cardiac dysfunction
in pressure-overloaded heart of mice. Biochem Biophys Res Commun 2006;340:
1125–1133.
70. Razeghi P, Baskin KK, Sharma S, Young ME, Stepkowski S, Essop MF et al. Atrophy,
hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin
proteasome system in the rat heart. Biochem Biophys Res Commun 2006;342:
361–364.
71. Balasubramanian S, Mani S, Shiraishi H, Johnston RK, Yamane K, Willey CD et al.
Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocar-
dium is accompanied by changes in specific E3 ligases. J Mol Cell Cardiol 2006;41:
669–679.
72. Sultan K, Schlossarek S, Englmann D, Vignier N, Eschenhagen T, Carrier L. Altera-
tions of the ubiquitin-proteasome system in cardiomyopathic cMyBP-C mice.
(Abstract). J Mol Cell Cardiol 2007;42:S167.
73. Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn MJ. Hyperubiquitination
of proteins in dilated cardiomyopathy. Proteomics 2003;3:208–216.
74. Birks EJ, Latif N, Enesa K, Folkvang T, Luong le A, Sarathchandra P et al. Elevated
p53 expression is associated with dysregulation of the ubiquitin-proteasome
system in dilated cardiomyopathy. Cardiovasc Res 2008;79:472–480.
75. Hedhli N, Wang L, Wang Q, Rashed E, Tian Y, Sui X et al. Proteasome activation
during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22. Cardiovasc Res
2008;77:497–505.
76. Rehwinkel J, Raes J, Izaurralde E. Nonsense-mediated mRNA decay: target
genes and functional diversification of effectors. Trends Biochem Sci 2006;31:
639–646.
77. Usuki F, Yamashita A, Kashima I, Higuchi I, Osame M, Ohno S. Specific inhibition
of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the
phenotype of Ullrich disease fibroblasts. Mol Ther 2006;14:351–360.
78. Kerem E. Pharmacologic therapy for stop mutations: how much CFTR activity is
enough? Curr Opin Pulm Med 2004;10:547–552.
79. Politano L, Nigro G, Nigro V, Piluso G, Papparella S, Paciello O et al. Gentamicin
administration in Duchenne patients with premature stop codon. Preliminary
results. Acta Myol 2003;22:15–21.
80. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob
Agents Chemother 1999;43:1003–1012.
81. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Pharmacogenomics
2005;6:27–36.
82. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S et al. Safety,
tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense
mutation suppressor, following single- and multiple-dose administration to
healthy male and female adult volunteers. J Clin Pharmacol 2007;47:430–444.
83. Wood M, Yin H, McClorey G. Modulating the expression of disease genes with
RNA-based therapy. PLoS Genet 2007;3:e109.
84. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C et al. Suppres-
sion of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome
system. Hypertension 2008;51:302–308.
85. Stansfield WE, Tang RH, Moss NC, Baldwin AS, Willis MS, Selzman CH. Protea-
some inhibition promotes regression of left ventricular hypertrophy. Am J Physiol
Heart Circ Physiol 2008;294:H645–H650.
86. Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, Liu H et al. Proteasome inhi-
bition decreases cardiac remodeling after initiation of pressure overload. Am J
Physiol Heart Circ Physiol 2008;295:H1385–H1393.
87. Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma
patient due to proteasome inhibitor bortezomib. Int J Hematol 2008;88:219–222.
88. Orciuolo E, Buda G, Cecconi N, Galimberti S, Versari D, Cervetti G et al. Unex-
pected cardiotoxicity in haematological bortezomib treated patients. Br J Haema-
tol 2007;138:396–397.
89. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treat-
ment combined with chemotherapy in a non-small cell lung cancer patient: a case
report. BMC Cancer 2006;6:129.
90. Weissman AM, Yang Y, Kitagaki J, Sasiela CA, Beutler JA, O’Keefe BR. Inhibiting
Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating
system in cancer. Ernst Schering Found Symp Proc 2008;171–190.
91. Willis MS, Schisler JC, Portbury AL, Patterson C. Build it up-tear it down: protein
quality control in the cardiac sarcomere. Cardiovasc Res 2009;81:439–448.
92. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE et al. Pro-
teasome inhibitor (MG-132) treatment of mdx mice rescues the expression and
membrane localization of dystrophin and dystrophin-associated proteins. Am J
Pathol 2003;163:1663–1675.
L. Carrier et al.338
